[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pandemic optimism, excess deaths pessimism", "description": "UK, Zoe symptom study\n\nhttps://health-study.joinzoe.com/data\n\nDaily new cases = 106,548\n\nCurrent symptomatic prevalence = 1,488,559\n\nUK official data\n\nhttps://coronavirus.data.gov.uk\n\nPatients admitted, 4,124 down 14% (past 7 days)\n\nWith covid or for covid?\n\nDeaths, 419, down 38% (past 7 days)\n\nONS latest\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nW/E 23rd August, prevalence\n\n1.64% in England (1 in 60 people)\n\n1.56% in Wales (1 in 65 people) \n\n1.95% in Northern Ireland (1 in 50 people) \n\n1.82% in Scotland (1 in 55 people)\n\nReinfections within the omicron wave\n\n14.6%\n\nAlpha, 1.8%\n\nDelta, 1%\n\nRisk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMc2209479?query=TOC&cid=NEJM%20eToc,%20September%201,%202022%20DM1402792_NEJM_Non_Subscriber&bid=1141953912\n\nhttps://www.nejm.org/doi/suppl/10.1056/NEJMc2209479/suppl_file/nejmc2209479_appendix.pdf\n\nWuhan-Hu-1  55.7%\n\nAlpha   58.8%\n\nDelta   64.5%\n\nBA.1 / BA.2  76.8% \n\n(UK, 84.4%)\n\nLong covid\n\n2.0 million people in private households in the UK (3.1%)\n\nOf those\n\n83% symptoms at least 12 weeks\n\n45% at least one year\n\n22% at least two years\n\nSymptoms\n\nFatigue, 62%\n\nShortness of breath, 37%\n\nDifficulty concentrating, 33%\n\nMuscle ache, 31%\n\nSymptoms adversely affected the day-to-day activities\n\n1.5 million people, (73% of those with SRLC)\n\nChina, millions in Covid lockdown\n\nhttps://www.theguardian.com/world/2022/aug/31/china-places-millions-into-covid-lockdown-again-as-economy-continues-to-struggle\n\nChina, cases, + 1,717 cases, majority asymptomatic\n\nSporadic cases around China\n\nSouthern cities of Shenzhen and Guangzhou\n\nNorthern port city of Dalian\n\nWestern metropolis of Chengdu to Shijiazhuang\n\nCentral Hebei province\n\nVarying levels of restrictions, closure of venues and restaurants\n\nDelayed school reopening\n\nForeign visitors, more than a week of quarantine hotels, sanitary conditions often poor\n\nMasking and regular testing, close contacts forcibly transported to field hospitals\n\nWorld Health Organization, China\u2019s policy unsustainable\n\nAnbound Research Center\n\nPresident Xi Jinping\u2019s government, \n\nPreventing the risk of economic stall should be the priority task\n\nModerna sues Pfizer and BioNTech \n\nhttps://www.washingtonpost.com/business/2022/08/26/moderna-pfizer-covid-lawsuit/?utm_campaign=wp_to_your_health&utm_medium=email&utm_source=newsletter&wpisrc=nl_tyh\n\nhttps://www.documentcloud.org/documents/22266043-moderna-complaint?responsive=1&title=1\n\nMODERNA SUES PFIZER AND BIONTECH FOR INFRINGING PATENTS CENTRAL TO MODERNA'S INNOVATIVE MRNA TECHNOLOGY PLATFORM\nAUGUST, 26, 2022\n\nhttps://investors.modernatx.com/news/news-details/2022/Moderna-Sues-Pfizer-and-BioNTech-for-Infringing-Patents-Central-to-Modernas-Innovative-mRNA-Technology-Platform/default.aspx\n\nModerna Chief Legal Officer Shannon Thyme Klinger\n\nWe believe that Pfizer and BioNTech unlawfully copied Moderna\u2019s inventions, and they have continued to use them without permission\n\nPfizer\n\nWe are surprised by the litigation given the Pfizer/BioNTech COVID-19 vaccine was based on BioNTech\u2019s proprietary mRNA technology and developed by both BioNTech and Pfizer", "link": "https://www.youtube.com/watch?v=yPOEU1qCW_w", "date_published": "2022-09-03 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "UK confusing vaccination guidelines", "description": "Green book, JCVI advises that breastfeeding women should be offered any suitable COVID-19 vaccine.\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1098808/Greenbook-chapter-14A-17August2022.pdf\n\n\n(Updated, 17th August, 2022)\n\nSummary of the Public Assessment Report. For covid-19 vaccine, Pfizer/BioNTec\n\nhttps://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccine\n\nWomen who are breastfeeding should also not be vaccinated. \n\n(Updated, 16th August, 2022)\n\n\n\nSummary of the Public Assessment Report\n\nAuthorisation for Temporary Supply, COVID-19 mRNA Vaccine BNT162b2 (BNT162b2 RNA) concentrate for solution for injection\n\nDepartment of Health and Social Care (DHSC), Pfizer Limited & BioNTech Manufacturing, GmbH\n\nhttps://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccine\n\nUpdated, 16th August, 2022\n\nReproductive and developmental toxicity\n\nFertility and early embryonic development and embryofoetal development\n\nA combined fertility and developmental study (including teratogenicity and postnatal investigations) in rats is ongoing.\n\nPrenatal and postnatal development, including maternal function\n\nNo such studies have been done.\n\nStudies in which the offspring (juvenile animals) are dosed and/or further evaluated\n\nNo such studies have been done.\n\nLocal tolerance\n\nNo such studies have been done. \n\nThe assessments made as part of the general toxicity study should suffice and a separate study is not needed.\n\nOther toxicity studies\n\nNo such studies have been done.\n\nToxicity conclusions\n\nThe absence of reproductive toxicity data is a reflection of the speed of development to first identify and select COVID-19 mRNA Vaccine BNT162b2 for clinical testing and its rapid development to meet the ongoing urgent health need. \n\nIn principle, a decision on licensing a vaccine could be taken in these circumstances without data from reproductive toxicity studies animals, \n\nbut there are studies ongoing and these will be provided when available. \n\nIn the context of supply under Regulation 174, \n\nit is considered that sufficient reassurance of safe use of the vaccine in pregnant women cannot be provided at the present time: \n\nhowever, use in women of childbearing potential could be supported,\n\nprovided healthcare professionals are advised to rule out known or suspected pregnancy prior to vaccination. \n\nWomen who are breastfeeding should also not be vaccinated. \n\nGreen book, updated 17th August 2022\n\nSpecific population groups \n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1098808/Greenbook-chapter-14A-17August2022.pdf\n\nPregnancy \n\nThere is no known risk associated with giving inactivated, recombinant viral or bacterial vaccines or toxoids during pregnancy or whilst breastfeeding (Kroger et al, 2013). \n\nDevelopmental and reproductivity testing of the Pfizer BioNTech, Moderna and AstraZeneca vaccines in animals have not raised any concerns. \n\nJCVI has therefore advised that women who are pregnant should be recommended to receive primary immunisation, \n\nand that pregnancy is considered a clinical risk group for the autumn booster programme. \n\nRoutine questioning about last menstrual period and/or pregnancy testing is not required before offering the vaccine. \n\nSurveillance of the inadvertent administration of COVID-19 vaccines in early pregnancy is being conducted for the UK by the UK Health Security Agency Immunisation and Vaccine Preventable Diseases Division, to whom such cases should be reported.1 \n\nThis surveillance is being undertaken to document safety in women who unknowingly receive a vaccine in early pregnancy\n\nBreastfeeding \n\nThere is no known risk associated with being given a non-live vaccine whilst breastfeeding. \n\nJCVI advises that breastfeeding women should be offered any suitable COVID-19 vaccine.", "link": "https://www.youtube.com/watch?v=7gLIay852jM", "date_published": "2022-09-02 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]